Reformulary Group’s Expert Committee meets each month to review and evaluate new drugs on the market and make recommendations with respect to their placement on the Reformulary. The Committee also conducts reviews of entire classes of drugs. This typically happens when a number of new drugs within a drug class have entered the market and/or when new clinical evidence is published that warrants a new review.

Changes to reimbursement for diabetes medication

In November 2018, the Reformulary Expert Committee undertook a comprehensive review of all diabetes medications. The Committee studied updated guidelines published by Diabetes Canada, as well as data from recent clinical studies.

How this will affect my coverage?

As a result of this research, we made changes to tier placements for certain diabetes medications. Members taking these drugs benefit from increased reimbursement, meaning they pay a lower co-pay. The drugs affected by these changes are as follows:

Drugs now preferred, on Tier 1 (from Tier 2)
- FORXIGA (dapagliflozin propanediol monohydrate)
- INVOKANA (canagliflozin)
- JARDIANCE (empagliflozin)
- SYNJARDY (empagliflozin + metformin)
- XIGDUO (dapagliflozin + metformin)

Drugs now on Tier 2 (from Tier 3)
- VICTOZA (liraglutide)
- OZEMPIC (semaglutide)
- INVOKAMET (canagliflozin + metformin)

For more information visit: [www.drugfinder.ca](http://www.drugfinder.ca)

Did you know...

Reformulary Group launches its Cannabis Standard in March – the first evidence-based medical cannabis formulary and research platform for patients. The platform uses evidence to help patients determine if they are a good candidate for medical cannabis and works to find the right product for the patient’s specific conditions and symptoms.

If you’re interested and require more information, please visit: [www.cannabisstandard.com](http://www.cannabisstandard.com)